Ranibizumab versus Bevacizumab for Ophthalmic Diseases Related to Neovascularisation: A Meta-Analysis of Randomised Controlled Trials

BACKGROUND: Bevacizumab is believed to be as effective and safe as ranibizumab for ophthalmic diseases; however, its magnitude of effectiveness and safety profile remain controversial. Thus, a meta-analysis and systematic review appears necessary. METHODS: PubMed and EMBASE were systematically searc...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bin, Wu, Haixiang, Liu, Xiaoyan, Lin, Houwen, Li, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077727/
https://www.ncbi.nlm.nih.gov/pubmed/24983855
http://dx.doi.org/10.1371/journal.pone.0101253

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077727/
https://www.ncbi.nlm.nih.gov/pubmed/24983855
http://dx.doi.org/10.1371/journal.pone.0101253

Ejemplares similares